Return to Faculty,Faculty


Agnes Cha

Associate Professor, Pharmacy Practice

Pharm. D., University of Illinois at Chicago, Chicago, ILPost Graduate Year-1 Pharmacy Residency, Veteran Affairs – New York Harbor Healthcare System, New York, NYPost Graduate Year-2 Ambulatory Care Residency, The Brooklyn Hospital, Brooklyn, NY


Dr. Agnes Cha graduated summa cum laude from the University of Illinois College of Pharmacy in Chicago, IL. Dr. Cha moved to NYC to pursue her interest in HIV/AIDS and ambulatory care. She completed a Post Graduate Year-1 Pharmacy Practice Residency at the Veterans Affairs Hospital in New York, NY and a Post Graduate Year-2 Ambulatory Care Residency with a focus on HIV Primary Care at the Brooklyn Hospital Center. Dr. Cha has obtained certification as an HIV Pharmacist by the American Academy of HIV Medicine and is also a Board Certified Ambulatory Care Pharmacist. Dr. Cha is currently an Associate Professor of Pharmacy Practice at LIU College of Pharmacy and has been practicing as an HIV clinical pharmacist at a HIV Primary Care clinic affiliated with the Brooklyn Hospital Center. She has implemented an interdisciplinary practice model and promotes pharmacist involvement on the medical team. She has also initiated a pharmacist-run Hepatitis C clinic and manages co-infected patients. Her passion centers on caring for HIV positive patients, both treatment naïve and experienced, and their co-morbidities as pharmacotherapy management becomes more complex. Dr. Cha serves as a preceptor for the Brooklyn Hospital Center's pharmacy residency program, for PGY1, PGY2-ID, and PGY-2 ambcare residents where she is a primary investigator for several research projects and oversees the Antiretroviral Stewardship Program. Dr. Cha also serves as a Director-At-Large for the Royal Counties chapter of New York State Council of Health-Systems Pharmacists (NYSCHP). She is also a strong advocate for expanding student experiences in resource poor countries through the International Pharmacy Practice & Public Health elective rotation.


  • Del Bello D, Cha A*, Sorbera M, Bichoupan K, Levine C, Doyle E, Harty A, Patel N, Ng M, Gardenier D, Odin J, Schiano TD, Fierer DS, Berkowitz L, Perumalswami PV, Dieterich DT, Branch AD. “Real-world sustained virologic response rates of sofosbuvir-containing regimens in patients coinfected with hepatitis C and HIV” Clin Infect Dis. 2016; Jun 15;62(12):1497-504. doi: 10.1093/cid/ciw119. Epub 2016 Mar 1.] Co-first author (*alternate corresponding author).
  • Cha A, Besignano-Long AR, Rothberger N, Shah B. “Reversibility of renal dysfunction after discontinuation of tenofovir.” J Am Pharm Assoc. 2016; May-Jun; 56(3):280-3. [DOI: 10.1016/j.japh.2016.02.013].
  • Cha A, Elsamadisi P, Su CP, Phipps E, Birnbaum JM. “Prevention of perinatal transmission of zidovudine- and nevirapine- resistant HIV.” Am J Health Syst Pharm. 2016; Apr 1; 73(7):451-5. [DOI: 10.2146/ajhp150620.].
  • Elsamadisi P, Cha A, Kim E, Latif S. “Statin use with the ATP III guidelines compared to the 2013 ACC/AHA guidelines in HIV primary care patients” J Pharm Pract. 2015; Nov 18; Epub ahead of print. [DOI: 10.1177/0897190015611774].
  • Billedo J, Berkowitz L, Cha A*. “Evaluating the impact of a pharmacist-led antiretroviral stewardship program on reducing drug interactions in HIV-infected patients” J Int Assoc Provid AIDS Care. 2015; Aug 19; Epub ahead of print. [DOI: 10.1177/2325957415600700] *Corresponding author.
  • Cope R, Berkowitz L, Arcebido R, Yeh JY, Trustman N, Cha A*. “Evaluating the effects on an interdisciplinary practice model with pharmacist collaboration on HIV patient co-morbidities” AIDS Patient Care STDS. 2015; Aug;29(8):445-53. [DOI: 10.1089/apc.2015.0018] *Corresponding author.
  • Cha, Agnes. “Chapter 37: HIV/AIDS” Primary Care, 2nd Edition: An Interprofessional Perspective. Ed. Joanne K. Singleton. New York: Springer Publishing Company, 2015. 555-585. Print.
  • Cha A, Budovich A. “Sofosbuvir: A new oral once-daily agent for the treatment of hepatitis C virus infection” Pharmacy & Therapeutics. 2014; 39(5): 345-352.
  • Bias TE, Venugopalan V, Berkowitz LB, Cha A. “Incidence of antiretroviral drug interactions during hospital course: The role of a pharmacist-led antiretroviral stewardship” J Pharm Technol. 2014; 30(2): 48-53. [DOI 10.1177/8755122513500919]
  • Vachirasudlekha B, Cha A, Berkowitz L, Shah B. “Interdisciplinary HIV care - Patient perceptions.” Int J Health Care Qual Assur. 2014; 27(5): 405-413. [DOI 10.1108/IJHCQA-01-2013-0007].
  • Cha A, Shaikh R, Williams S, Berkowitz L. “Rapid reduction of HIV viral load in late pregnancy with raltegravir: a case report.” J Int Assoc Provid AIDS Care. 2013; 12 (5): 312-4 [DOI 10.1177/2325957413488176].
  • Gatti D, Cha A. “Apparent interaction between telaprevir and warfarin in a patient with chronic hepatitis C viral infection.” Am J Health-Syst Pharm. 2012; 69:2062-65 [DOI: 10.2146/ajhp120220].
  • Cha A. “Ask the HIV Specialist: Elevated (Liver) Concerns.” Positively Aware. May/June 2011; 41.
  • Berrios-Colon E, Cha A. The treatment and management of atrial fibrillation. US Pharmacist. 2010, 35(2):26-38.

Lectures and Presentations

Sorbera M, Cha A, Del Bello D, Bichoupan K, Yalamanchili R, Harty A, Ng M, Stivala A, Gardenier D, Khaitova V, Salomon N, Mildvan D, Perlman D, Liu L, Odin J, Schiano T, Perumalswami P, Fierer D, Kotler D, Dieterich D, Branch A, “Evaluation of Sofosbuvir and Simeprevir Combination Therapy in an HCV/HIV Co-Infected Population”, 54th Annual Assembly: Taking it to the Top, Bolton Landing NY, 2015

Del Bello D, Bichoupan K, Levine C, Cha A, Perlman D, Salomon NH, Kotler D, Fierer DS, Dieterich DT, Branch AD, “Real-world Data on HIV-Positive Patients with HCV Treated with Sofosbuvir and/or Simeprevir”, Conference on Retroviruses and Opportunistic Infections (CROI), Seattle WA, 2015

Elsamadisi P, Cha A, “Prevention of Perinatal Transmission in an HIV Infected Mother with Documented Resistance to Zidovudine and Nevirapine: A Case Report”, ASHP Midyear, Anaheim CA, 2014

Hammon K, Ocheretyaner E, Wong E, Cha A, “HIV: Embracing Medication Adherence & Smoking Cessation”, ASHP Midyear, Anaheim CA, 2014

Swamy S, Cha A, Yuseff J, Sharma R, Virologic Outcomes with Elvitegravir (EVG) and Raltegravir (RAL) in an Urban Cohort” And: “Statin Use in the ATP III Guidelines Compared to the 2013 ACC/AHA Guidelines in HIV Primary Care Patients”, ACCP Annual Meeting, Austin TX, 2014

Cope R, Cha A, Omoloju A, “Evaluation of budesonide use with interacting antiretroviral medications”, ASHP, Orlando FL, 2013

Cha A, Billedo JS, Berkowitz L , “Impact of clinical pharmacists’ intervention through an Antiretroviral Stewardship Program (ARVSP)”, Making a Difference in Infectious Diseases Pharmacotherapy (MAD-ID), Orlando FL, 2013

Arcebido A, Rubin R, Cha A, “Pharmacist interventions through collaborate drug therapy management in an interdisciplinary HIV clinic”, 52nd Annual Assembly: Medication Safety, Verona NY, 2012

Gim S, Cha A, “An international pharmacy practice and public health Advanced Pharmacy Practice Experience (APPE) in Port-au-Prince, Haiti”, ACCP, Kissimmee FL, 2012

Vachirasudlekha B, Berkowitz L, Cha A, “Treatment of acute hepatitis C with telaprevir, peginterferon alfa-2b, and ribavirin”, ASHP; New Orleans, LA, 2011

Cha A, Berrios-Colon E, Berkowitz L.  “Evaluating the management of diabetes mellitus type-2 in HIV-infected patients”, American Conference for Treatment of HIV; Denver CO, 2010

Books/ Book Chapters

Cha, Agnes. “Chapter 37: HIV/AIDS” Primary Care, 2nd Edition: An Inter-professional Perspective. Ed. Joanne K. Singleton. New York: Springer Publishing Company, 2015. 555-585. 


NYSCHP Research and Education Foundation Infectious Diseases Research Award - April 2015

NYSCHP Research and Education Foundation HIV Pharmacy Research Award - May 2014

Preceptor of the Year, Brooklyn Hospital Pharmacy Residency Program - June 2011

Research Synopsis

HIV/AIDS and Hepatitis C: Research centers on the management of patients with HIV and their comorbidities. Involved in evaluating the efficacy and safety of antivirals for HIV/Hepatitis C coinfection, evaluating interdisciplinary practice models and the impact of clinical pharmacists on patient care, reducing clinically significant drug-drug interactions with antiretrovirals, evaluating the reversibility of tenofovir related renal dysfunction, and applying cardiovascular risk assessment tools in HIV patients.

Current projects include assessing real-world experience with higher than recommended doses of lamivudine in varying degrees of renal impairment, and observing the clinical significance of dolutegravir and metformin co-administration.